Source: International Congress 2014 – Asthma and COPD management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. C. Chou, C. H. Wang, H. P. Kuo (Taipei, Taiwan). Clinical effectiveness of anti-IgE therapy in allergic severe asthma. Eur Respir J 2014; 44: Suppl. 58, 908

Member's Comments

No comment yet.

Related content which might interest you: Experience with omalizumab in patients with moderate and severe asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Combined therapy of asthma and allergic rhinitis Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Clinical effectiveness of anti-IgE therapy in severe asthma with fungus sensitization Source: International Congress 2014 – Non inflammatory monitoring of airway diseases Year: 2014 Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Efficacy of carbamazepine in treatment of bronchial asthma Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 When needed use of inhaled steroids in children with asthma Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management Year: 2014 Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Sputum eosinophilia in severe allergic asthma is not a reliable marker of omalizumab treatment Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Comparison of three modalities of corticosteroids administration in chronic rhinosinusitis Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014 HDM sublingual AIT tablet is well-tolerated and effective in partly and uncontrolled allergic asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 Effect of oral corticosteroids on symptomatic reflux in severe allergic asthma: Is there a link? Source: International Congress 2014 – The assessment of comorbidities Year: 2014 Characteristics of the adult corticosteroid-dependent severe asthma in UBIOPRED consortium Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 The ’real-life’ long-term efficacy of omalizumab in severe persistent IgE-mediated allergic asthma in Malta Source: International Congress 2016 – Asthma management Year: 2016 Improved effects of aerosol-type fluticasone propionate/formoterol combination on residual asthmatic inflammation in distal airways of patients with moderate asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Long-acting anticholinergics in the treatment of severe asthma with irreversible airway obstruction Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Effect of cromolyn inhaler on resistant neutrophilic cough variant of asthma, A phase two clinical trial Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014